Skip to main content

Vonoprazan Disease Interactions

There are 2 disease interactions with vonoprazan.

Moderate

Proton pump inhibitors (applies to vonoprazan) bone fractures

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Osteoporosis

Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine. The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.

References

  1. (2001) "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc
  2. (2001) "Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals
  3. (2001) "Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals
  5. (2003) "Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc
  6. (2009) "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America
  7. (2023) "Product Information. Voquezna (vonoprazan)." Phathom Pharmaceuticals, Inc
View all 7 references
Moderate

Vonoprazan (applies to vonoprazan) mineral metabolism

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Magnesium Imbalance, Hypocalcemia, Hypokalemia

Postmarketing cases of hypomagnesemia have been reported with vonoprazan. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients. Monitor magnesium and calcium levels regularly in patients with a preexisting risk of hypocalcemia (e.g., hypoparathyroidism). Monitor magnesium levels prior to initiating therapy with vonoprazan in all patients, and then periodically while on treatment. Monitor magnesium levels closely in patients taking drugs that may have increased toxicity in the presence of hypomagnesemia (e.g., digoxin), or drugs that may cause hypomagnesemia (e.g., diuretics).

References

  1. (2023) "Product Information. Voquezna (vonoprazan)." Phathom Pharmaceuticals, Inc

Vonoprazan drug interactions

There are 203 drug interactions with vonoprazan.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer